Saad Islam, Salem Suzan
Department of Periodontology and Oral Medicine, College of Dentistry, Qassim University, KSA.
Alexandria University Hospitals, Alexandria University, Egypt, Phone: 0966531015435, e-mail:
J Contemp Dent Pract. 2018 Oct 1;19(10):1204-1213.
The current study will attempt to throw light on the role of desmoglein 1 and desmoglein 3 in the pathogenesis of erosive lichen planus and their response to topical application of tacrolimus.
Twenty patients with erosive oral lichen planus received tacrolimus ointment three times daily for eight weeks. Assessments using the clinical score and a visual analog scale were recorded at each visit. Serum concentrations of circulating autoantibodies to desmoglein 1 and desmoglein 3 will be determined by enzyme-linked immunosorbent assay (ELISA) at baseline, four weeks and eight weeks after treatment. Statistical software SPSS v.17.0 was used for statistical analysis.
All patients showed significant improvement in all outcomes within the follow-up periods when compared with the baseline (p < 0.05). The mean value of the visual analog scale were 8.30 ± 1.49, 4.15 ± 1.14, 2.10 ± 0.91, 0.90 ± 0.79, and 0.0 ± 0.0 starting from baseline to the end of follow up period. The mean value of the clinical score were 4.7 ± 0.48, 2.9 ± 1.29, 1.8 ± 1.32, 1.31 ± 0.69, and 0.69 ± 0.09 starting from baseline to the end of follow-up period. There was a significant decrease in the levels of anti-Dsg1 and anti-Dsg3, during the follow-up period (p < 0.05).
The concluded data suggest that antibodies against desmoglein 1 and desmoglein 3 seem to play a key role in the pathogenesis of oral lichen planus. Also, there is a significant decrease in the level of anti-Dsgl and anti-Dsg3 autoantibodies with topical tacrolimus 0.1% ointment.
Monitoring the serum level of antibodies against keratinocyte cadherins Dsg 1 and Dsg 3 can be used to evaluate the effect of topical application of tacrolimus on Erosive Oral lichen planus.
本研究旨在阐明桥粒芯糖蛋白1和桥粒芯糖蛋白3在糜烂性扁平苔藓发病机制中的作用及其对局部应用他克莫司的反应。
20例糜烂性口腔扁平苔藓患者每天3次外用他克莫司软膏，持续8周。每次就诊时记录使用临床评分和视觉模拟量表进行的评估。在基线、治疗后4周和8周时，通过酶联免疫吸附测定（ELISA）测定血清中针对桥粒芯糖蛋白1和桥粒芯糖蛋白3的循环自身抗体浓度。使用统计软件SPSS v.17.0进行统计分析。
与基线相比，所有患者在随访期间所有指标均有显著改善（p < 0.05）。从基线到随访期末，视觉模拟量表的平均值分别为8.30±1.49、4.15±1.14、2.10±0.91、0.90±0.79和0.0±0.0。从基线到随访期末，临床评分的平均值分别为4.7±0.48、2.9±1.29、1.8±1.32、1.31±0.69和0.69±0.09。随访期间，抗桥粒芯糖蛋白1和抗桥粒芯糖蛋白3水平显著降低（p < 0.05）。
所得数据表明，针对桥粒芯糖蛋白1和桥粒芯糖蛋白3的抗体似乎在口腔扁平苔藓的发病机制中起关键作用。此外，外用0.1%他克莫司软膏可使抗桥粒芯糖蛋白1和抗桥粒芯糖蛋白3自身抗体水平显著降低。
监测针对角质形成细胞钙黏蛋白桥粒芯糖蛋白1和桥粒芯糖蛋白3的抗体血清水平可用于评估外用他克莫司对糜烂性口腔扁平苔藓的疗效。
